locally advanced Siewert III Esophagogastric Junction Cancer and upper and middle part of gastric cancer
Conditions
Interventions
TLTG overlap:TLTG overlap
LATG:LATG
Sponsors
Xijing Hospital, the Fourth Military Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) age between 18–65 years; 2) Siewert type III adenocarcinoma of esophagogastric junction and upper and middle part of gastric cancer; 3) not received neoadjuvant chemotherapy; 4) feasible to perform D2 (lymph node dissection according to the Japanese gastric cancer guidelines 2010 third edition recommended) radical total gastrectomy (R0 resection), 5) absence of distant metastases and surrounding adjacent organ invasion on preoperative contrast enhanced computed tomography (CT) chest and abdomen; 6) preoperative staging cT2-4aN0-3M0 (according to AJCC-7th TNM tumor staging); 7) voluntary participation in the study and provide informed consent; 8) preoperative ECOG score of 0 to 2; 9) preoperative white blood cells (WBC) >= 3 x10^9 / L, absolute neutrophil count (NEU) >= 1.5 x10^9/L, platelet (PLT) >= 100 x10^9/L; 10) preoperative ASA score I-III.
Exclusion criteria
Exclusion criteria: 1) contraindications for laparoscopic surgery; 2) uncontrolled severe medical diseases, including unstable angina or myocardial infarction within 6 months, congestive heart failure greater than NYHA 2, arrhythmia requiring antiarrhythmic drugs, thrombosis or embolic events within 6 months, severe central nervous system, blood system disease or heart, lung, liver, kidney dysfunction and immunodeficiency, liver cirrhosis, portal hypertension, splenomegaly; 3) trauma, fracture, or serious surgery within 6 weeks before the start of the study; 4) autologous bone marrow transplantation or stem cell rescue treatment within 4 months before the start of the study; 5) history of allogeneic organ transplantation; 6) pregnant or lactating women; 7) serious mental illness; 8) history of previous esophageal or gastric surgery; 9) history of other malignant tumors within 5 years; 10) emergency surgery; 11) participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall complications occurred within 30 days after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| 3-year disease free survival;3-year overall survival; | — |
Countries
China
Contacts
Public ContactGang Ji
Xijing Hospital, the Fourth Military Medical University
Outcome results
None listed